Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 814 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Benjamin Hohl also recently made the following trade(s):
- On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
- On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.
- On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
- On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total value of $50,660.00.
- On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total value of $95,795.00.
- On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $27,282.23.
- On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total value of $140,070.00.
Enliven Therapeutics Stock Performance
ELVN opened at $28.97 on Thursday. The company’s 50-day simple moving average is $24.52 and its two-hundred day simple moving average is $22.88. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $30.03. The stock has a market capitalization of $1.36 billion, a P/E ratio of -15.01 and a beta of 1.10.
Institutional Investors Weigh In On Enliven Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in Enliven Therapeutics in the 3rd quarter worth $256,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Enliven Therapeutics during the second quarter worth about $322,000. Marshall Wace LLP bought a new stake in Enliven Therapeutics during the 2nd quarter valued at approximately $4,489,000. First Turn Management LLC bought a new stake in Enliven Therapeutics during the 2nd quarter valued at approximately $9,657,000. Finally, Nicholas Investment Partners LP purchased a new position in Enliven Therapeutics in the 2nd quarter worth approximately $1,310,000. Institutional investors own 95.08% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.
Check Out Our Latest Research Report on Enliven Therapeutics
About Enliven Therapeutics
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- Insider Buying Explained: What Investors Need to Know
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How is Compound Interest Calculated?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Differences Between Momentum Investing and Long Term Investing
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.